908PD - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

L Albiges,B.I Rini,J B A G Haanen,R.J Motzer,C.K Kollmannsberger,S Negrier,F Nole,J Bedke,M.A Bilen,P Nathan,Y Tomita,B Huang,K.A Ching,A Chudnovsky,P.B Robbins,A Di Pietro,D Thomaidou,T.K Choueiri

doi:10.1093/annonc/mdz249.007

908PD - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

L Albiges, B.I Rini + Show 16 more

Open Access

https://doi.org/10.1093/annonc/mdz249.007

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 17	License type: elsevier-specific: oa user license

Affiliation: Memorial Sloan Kettering Cancer Center, University of Tübingen, Emory University, Niigata University, Brigham and Women's Hospital

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

908PD - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

Full Text